EUVIMEDEUVIMED entdecken
LeserbriefFallberichtOpen Access · CC BY-NC-ND 4.0

Plasma 3‐ O ‐Methyldopa Concentration Monitoring for Treatment Optimization in Foslevodopa/Foscarbidopa Infusion: Implications for Corrected Levodopa Availability: A Case Report

Shohei Okusa iD, Kotaro Okada, Yoshihiro Nihei iD, Risano Sakai, Takeshi Akiyoshi iD, Tomonori Nukariya, Jin Nakahara iD, Hisakazu Ohtani iD, Morinobu Seki iD

Movement Disorders Clinical Practice · 03.08.2026

DOI: 10.1002/mdc3.70761 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 03.08.2026. Verfasst von Shohei Okusa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Keio University School of Medicine, Tokyo, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

3‐O‐methyldopaL‐type aminoParkinson's diseaseacid transporter 1continuous subcutaneous infusionfoslevodopa/foscarbidopa

Autor:innen und Institutionen

  • Department of Neurology, Keio University School of Medicine, Tokyo, Japan.
  • Parkinson's Disease Center, Keio University Hospital, Tokyo, Japan.
  • Center for Parkinson's Disease Research, Keio University, Tokyo, Japan.
  • Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Keio University, Tokyo, Japan.
  • Department of Clinical Pharmacy, Keio University School of Medicine, Tokyo, Japan.
  • Department of Pharmacy, Keio University Hospital, Tokyo, Japan.

ORCID-Profile: Shohei Okusa, Yoshihiro Nihei, Takeshi Akiyoshi, Jin Nakahara, Hisakazu Ohtani, Morinobu Seki

Zitieren

APA

Okusa, S., Okada, K., Nihei, Y., Sakai, R., Akiyoshi, T., Nukariya, T., Nakahara, J., Ohtani, H., & Seki, M. (2026). Plasma 3‐ O ‐Methyldopa Concentration Monitoring for Treatment Optimization in Foslevodopa/Foscarbidopa Infusion: Implications for Corrected Levodopa Availability: A Case Report. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70761

Vancouver

Okusa S, Okada K, Nihei Y, Sakai R, Akiyoshi T, Nukariya T, et al. Plasma 3‐ O ‐Methyldopa Concentration Monitoring for Treatment Optimization in Foslevodopa/Foscarbidopa Infusion: Implications for Corrected Levodopa Availability: A Case Report. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70761

BibTeX
@article{Okusa2026,
  author = {Okusa, Shohei and Okada, Kotaro and Nihei, Yoshihiro and Sakai, Risano and Akiyoshi, Takeshi and Nukariya, Tomonori and Nakahara, Jin and Ohtani, Hisakazu and Seki, Morinobu},
  title = {Plasma 3‐ O ‐Methyldopa Concentration Monitoring for Treatment Optimization in Foslevodopa/Foscarbidopa Infusion: Implications for Corrected Levodopa Availability: A Case Report},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  doi = {10.1002/mdc3.70761}
}
Kostenlos starten →